GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » 3-Year Revenue Growth Rate

Zenotech Laboratories (BOM:532039) 3-Year Revenue Growth Rate : 23.80% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories 3-Year Revenue Growth Rate?

Zenotech Laboratories's Revenue per Share for the three months ended in Mar. 2024 was ₹1.33.

During the past 12 months, Zenotech Laboratories's average Revenue per Share Growth Rate was -4.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 23.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 21.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 28.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Zenotech Laboratories was 89.90% per year. The lowest was -37.40% per year. And the median was 14.00% per year.


Competitive Comparison of Zenotech Laboratories's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenotech Laboratories's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zenotech Laboratories's 3-Year Revenue Growth Rate falls into.



Zenotech Laboratories 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Zenotech Laboratories  (BOM:532039) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Zenotech Laboratories 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zenotech Laboratories's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenotech Laboratories (BOM:532039) Business Description

Traded in Other Exchanges
N/A
Address
Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories (BOM:532039) Headlines

No Headlines